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Heterotopic ossiﬁcation (HO) is the formation of marrow-containing bone outside of the normal skeleton. Acquired HO
following traumatic events is a common and costly clinical complication. In contrast, hereditary HO is rarer, progressive, and
life-threatening. Substantial eﬀort has been directed towards understanding the mechanisms underlying HO and ﬁnding eﬃcient
treatments. However, one crucial limiting factor has been the lack of relevant animal models. This article reviews the major
currently available animal models, summarizes some of the insights gained from these studies, and discusses the potential future
challenges and directions in HO research.
1.Introduction
Heterotopic ossiﬁcation (HO) is the formation of marrow-
containing bone outside of the normal skeleton [1, 2].
Acquired HO following traumatic events, such as total joint
replacements (TJR) [3–5], spinal cord injury (SCI) [6],
traumatic brain injury (TBI) [7], fracture, muscular trauma,
or war-wounded patients [8, 9], is a common and costly
clinical complication. Hereditary HO, such as ﬁbrodysplasia
ossiﬁcans progressiva (FOP), is rare, progressive, and life
threatening [10]. The ﬁrst description of hereditary HO in
FOP was made in 1692 by Guy Patin. Acquired HO as a
complication of gunshot wounds was described by Dejerine
and Ceillier in 1918 [11]. 16%–53% of SCI (11,000 annually)
and TBI (1.4 million) patients and 40%–50% of TJR (1
million) patients will develop HO at some point.
About10%ofHOissymptomaticresultinginlimitations
in range of motion. Once acquired HO develops, surgical
removal is the only eﬀective treatment, normally followed
by local radiation or nonsteroidal anti-inﬂammatory agents
(NSAIDs) to prevent recurrence [12]. However, surgical
removal is costly, the eﬀectiveness of NSAIDs is variable,
and radiation has been associated with malignancies [13,
14]. Further, there is no eﬀective treatment for debilitating
hereditary HO, FOP [15].
Substantial eﬀort has been directed towards understand-
ing the mechanisms underlying HO and ﬁnding eﬃcient
treatments. However, one crucial limiting factor has been
the lack of relevant animal models. This paper reviews
the long and arduous eﬀorts to generate clinical relevant
animalmodelsandfocusesonthefeaturesofmajorcurrently
available models. It also summarizes some of the insights
gained from these studies and discusses the potential future
challenges and directions in HO research.
For the purposes of this paper, HO is deﬁned as a hetero-
geneous disorder characterized by pathologic endochondral
ossiﬁcation with hematopoietic bone marrow in soft tissues,
suchassubcutaneoustissue, skeletal muscle, or ﬁbroustissue
adjacent to joints. Similar pathologies lacking endochondral
ossiﬁcation, such as Progressive Osseous Heteroplasia [15,
16] or that containing no hematopoietic bone marrow,
such as ectopic calciﬁcation/mineralization [17] (also called
dystrophic calciﬁcation), are not included.
2. AnimalModels of HereditaryHO
A typical example of hereditary HO is FOP, which is char-
acterized by stereotyped patterned progressive ossiﬁcation
in soft tissues [18]. In this disorder, mutations in a bone
morphogenetic protein (BMP) receptor gene, ACVR1 [19],
result in dysregulation of BMP signaling that ultimately
leads to FOP [10, 20]. This mutant ACVR1 activates BMP
signaling in the absence of BMP ligand leading to BMP-
independent chondrogenesis that is enhanced by BMP2 Journal of Biomedicine and Biotechnology
ligands [21]. This indicates that mechanism-based animal
models that faithfully replicate the disorder virtually require
genetic modiﬁcations leading to enhanced BMP signaling.
Theoretically, there are at least ﬁve ways to modify and
enhance BMP signaling: (1) by introducing a hyperactive
BMP receptor, (2) by knocking out BMP inhibitors, (3)
by introducing high level of BMPs, (4) by overexpressing
speciﬁc BMP target genes, and (5) by modifying BMP
signaling indirectly through other factors that can interact
with components of BMP signaling pathway.
2.1.AnimalModelsThatIntroduceHyperactiveBMPReceptor.
Animal models that introduce hyperactive BMP receptor,
especially the recently found mutations in ACVR1, would
seem to be the most relevant model of FOP. However,
introducing a constitutively active ACVR1 mutation into
zebraﬁsh embryos failed to induce obvious HO even though
strong ventralization due to enhanced BMP signaling was
observed [20]. A genetically modiﬁed mouse model that
carries the same mutation has not yet been reported but
will likely be a valuable addition to the ﬁeld in the future.
Interestingly, a number of animals including domestic cats
[22–25], shepherd dog [26], pigs [27], and the Southeast
Asian mouse deer of the genus Tragulus [28]d e v e l o p
FOP-like conditions spontaneously. Even though the exact
genetic bases are still unknown, it is reasonable to think
that sporadic, spontaneous mutations in the BMP signaling
pathway, especially mutations in ACVR1, were likely respon-
sible for the observed FOP-like conditions. Further genetic
studies of these aﬀected animals hopefully will clarify this
issue. However, due to the rarity of the events and ethical
considerations, the practicality of these large animal models
as a drug testing platform is in question.
Kobayashi et al. [51] reported that Col2-caBmpr1a
transgenic mice that express constitutive active Bmpr1a
(caBmpr1a) under the control of rat type II collagen
promoter created enhanced BMP signaling. E17.5 transgenic
embryos showed severe skeletal abnormalities; the femur,
tibia, and patella were fused together, eliminating joint tis-
sues [51]. This study demonstrated that overactive BMP sig-
nalingthroughcaBMPR1Ainchondrocytesstimulateschon-
drocyte maturation toward hypertrophic diﬀerentiation, but
an HO phenotype was not reported in this model. Fukuda et
al. reported using a Cre-loxP system to conditionally express
a constitutively active ALK2 receptor (caALK2) to activate
BMP signaling, but this produced embryonic lethality [29].
Their data indicate that low levels of caAlk2 expression are
suﬃcient to transduce a suﬃc i e n ta m o u n to fB M Ps i g n a l i n g
to compromise normal development of embryos. We specu-
late that conditionally activating the caAlk2 expression with
late tissue-speciﬁc Cre in future studies might generate a
mouse model that is useful for study of HO.
2.2. Animal Models That Knock out BMP Inhibitors. Genetic
deletionofaBMPinhibitor is anotherstrategyforenhancing
BMP signaling and potentially producing an animal model
with an FOP-like phenotype. In fact, Noggin-/- mice have
some congenital skeletal defects, including congenital HO,
but Noggin-/- mice die soon after birth [30]. Mice with
targeted disruption of Chordin, another BMP inhibitor, also
die at birth, and they develop defects in inner and outer
ear development and show abnormalities in pharyngeal
and cardiovascular organization [31]. Mutation of another
mouse competitive BMP inhibitor gene, Gremlin, resulted
also in a severe abnormal skeletal pattern [52]. Interestingly,
conditional deletion of Gremlin by crossing the ﬂoxed mice
with osteocalcin promoter-driven cre (Oc-Cre) caused only
a transient increase in bone formation and bone mass, but
not HO [53]. Null mutation of less speciﬁc inhibitors of
BMP signaling, such as Dan [54] or Cerberus-like [55], did
not generate gross defects; these two mutant lines are born
alive and fertile without a postnatal HO phenotype. Thus,
although null mutation of genes encoding BMP inhibitors
provided insights into how enhanced BMP signaling aﬀects
embryonic development, especially skeletal development,
none of the mutant mouse lines generated by this strategy
are useful for postnatal HO studies. This likely reﬂects the
pleiotropic roles of BMP signaling in various tissues.
2.3. Animal Models That Overexpress BMP Ligand. The
rationale for enhancing BMP signaling by overexpressing
BMP ligand is straightforward, but this approach has met
a number of unexpected complications. Overexpression of
BMP4 under the control of many diﬀerent promoters does
not lead to postnatal HO. For example, HO does not develop
after overexpression of BMP4 under control of either the
keratin promoter (K14) [32] or the bovine cytokeratin IV
promoter [56]. Transgenic mice overexpressing BMP4 under
control of surfactant protein-C gene promoter die from
abnormally formed lungs [57]. Transgenic mice expressing
BMP4 in cartilage under the control of the Col11a2 pro-
moter/enhancer sequences die at birth due to respiratory
failure [58] while mice overexpressing human BMP4 under
control of mouse Msx1 minimal promoter develop no
visible abnormalities [33]. Overexpression of BMP2 under
the human αSM-actin promoter in an ApoE-deﬁcient back-
ground accelerates atherosclerotic intimal calciﬁcation in
transgenic lines but does not produce typical HO [59]. Mice
that overexpress BMP4 under the Nephrin promoter have
interesting defects in glomerular capillary formation but not
the HO phenotype [60].
The only exception has been mice that overexpress
BMP4under controlofthe neuron speciﬁcenolasepromoter
(Nse-BMP4). These mice develop a phenotype that closely
recapitulates the FOP phenotype and that also displays the
histological hallmarks of typical acquired HO [34]. These
ﬁndings suggest that overexpression of BMP itself may be
necessary but is not suﬃcient to generate the HO phenotype
and that the correct expression patterns or contexts are
crucial. We have extensively characterized the phenotype in
this transgenic mouse line and have used these mice, in
collaboration with other labs [39], to study diﬀerent aspects
of HO, including deﬁnition of the events that trigger HO,
the type of cells that respond to the trigger by diﬀerentiating
alongtheosteogeniclineage,andthemechanismsunderlying
the spread of HO [61].Journal of Biomedicine and Biotechnology 3
2.4. Animal Models That Overexpress a Speciﬁc BMP Target
Gene. If overexpression of BMP ligand can produce HO, it
is reasonable to think that expressing speciﬁc BMP target
genes might also be capable of copying the phenotype of
BMP overexpression. In fact, overexpression of MSX2, a
BMP target gene, can induce an HO-like phenotype. MSX2
overexpressionelicitedthephenotypeundercontrolofeither
an ubiquitous promoter, such as CMV, a tissue speciﬁc pro-
moter, such as TIMPl (tissue inhibitor of metalloproteinase
1), or the endogenous MSX2 promoter [35, 62]. Overex-
pression of another BMP target gene, Runx2, under the
type II collagen promoter also caused an HO-like phenotype
and ectopic expression of hypertrophic chondrocyte markers
[36]. These two models show that both MSX2 and Runx2
can partially mediate the osteogenic eﬀects of BMPs in vivo.
However, since the phenotypes in these two lines do not
closely mimic that of FOP, the relevance of these models
to the human disease is still unclear. Moreover, multiple
transgenic lines that overexpress other BMP target genes,
especially the Id family genes, that is, Id1-Id4 [63–65], have
failed to produce an HO phenotype. This could be partially
explained by the inadequate tissue speciﬁc promoters used in
generating these transgenic lines. However, the failure more
likelyindicatesthatnotallBMPtargetgenesareimportantin
mediating the HO phenotype, even though Id1 and Id3 are
positive factors in promotion of bone formation in vivo [65].
2.5. Animal Models That Overexpress Other Factors That
Indirectly Modify the BMP Signaling Pathway. Theoretically,
it is also possible to enhance the BMP signaling indirectly
through factors that can interact with components of the
BMP signaling pathway. For example, overexpression of
Fos in bone cells under control of an FBJ long terminal
repeat element (H2-FosLTR) resulted in the development of
calciﬁed tumors similar to HO, and Fos-ES cell chimeras
developed chondrosarcomas with high eﬃciency at all skele-
tal sites containing cartilage [37]. However, transgenic mice
that overexpress other related AP1 members (e.g., JUN and
FOSB) do not exhibit abnormalities, despite high expression
in bone tissue. Not surprisingly, further studies provided
evidence of speciﬁc interactions between the BMP-signaling
pathway and c-Fos, but not the other related AP1 members
in FOP-like lesions [38].
Overall, even though there are multiple ways to enhance
BMP signaling in vivo, only a few genetic modiﬁed animal
lines showed typical HO, or a phenotype resembling FOP.
Further, only one line, Nse-BMP4 transgenic mice, closely
recapitulated the major aspects of the FOP phenotype.
3. AnimalModels for AcquiredHO
Acquired HO usually follows traumatic events, such as
fracture, total hip arthroplasty, muscular trauma, spinal cord
injury, or central nervous system injury. It is a relatively
frequent clinical complication with a wide clinical spectrum
but normally it has a relatively benign course [12]. The etiol-
ogy of common acquired HO is still unclear, and multiple
contributing factors have been proposed including BMPs,
inﬂammation, prostaglandin E2, hypercalcemia, hypoxia,
abnormal nerve activities, immobilization, and disequilib-
rium of hormones [66, 67]. Lack of deep understanding
of underlying molecular mechanisms has directly hindered
the validation of existing animal models, and this also has
limited the development of new mechanism-based animal
models. Currently, there are several available animal models
that can produce typical HO: (1) heterotopic implantation
models, (2) hip arthroplasty model, (3) the immobilization
manipulation model (also called the Michelsson model), (4)
Achilles tenotomy model, (5) trauma-induced model, and
(6) models generated by injection of irritants and other
materials to muscle.
3.1. Heterotopic Implantation Model. Currently the most
commonly used animal model for HO involves the surgical
implantation of BMP containing matrix at heterotopic sites.
Implantation of demineralized bone matrix was ﬁrst used
by Urist in 1965 [68]; then Wozney et al. were able to
repeat the experiment using partially puriﬁed BMP proteins
[69]. Currently, the most widely used approach is BMP
matrigel implantation [39]; an advantage of this method
is that a chilled mix can be injected into heterotopic sites
as a liquid which gels on site at body temperature and
thereafter releases BMP4 continuously at the site. Many
modiﬁcations/variations of this method have been used
in diﬀerent species under diﬀerent conditions, including
introduction of a DNA construct that produces BMPs
[40], microbubble-enhanced transcutaneous sonoporation
of human BMP2 [70], nanogel-cross-linking hydrogel as
as c a ﬀold [41], implantation of a slow-release system of
polylacticacidandrhBMP-2,orsinteredporous-surfacedTi-
6Al-4V implants coated with native BMPs [71].
One interesting variation on this theme involves direct
injection into the heterotopic site of cells that have
osteogenic, and/or osteogenic factor producing potential,
such as bone marrow cells [42], or implantation of a diﬀu-
sion chamber containing such cells. Tested cell types have
included urinary tract epithelia [72], certain transformed
cells such as transformed human amnion cells (FL cells)
[73], Moloney sarcoma [74], and epithelial-like cells [75].
In a similar system, these cells are impregnated into ceramic
blocks to test their osteogenic activity [76] in the presence or
absence of an osteogenic inducer.
Another interesting approach takes advantage of the
osteoinductive ability of certain biomaterials, such as micro-
porous calcium phosphate ceramic particles [43], that do
not release BMP or other known osteogenic factors. The
mechanism of osteoinduction by such biomaterials is not
currently clear, although the geometry of the material is
thought to be important [77].
Generally, heterotopic implantation models are straight-
forward, repeatable, and mechanistically relevant to human
HO. However, certain limitations do exist: (1) they are
artiﬁcial systems that may create unphysiologically high
local concentrations of osteogenic factors in implanted sites
leading to eﬀects not relevant to the human disorder, (2) the
implantation is a local event and thus has limited ability to
mimic the potential eﬀects of the involvement of multiple4 Journal of Biomedicine and Biotechnology
systems, (3) diﬀerent variations of this method have variable
reliabilities and relevance to human conditions, (4) the
incidence of implantation-induced bone formation varies
depending upon the material or animal species. Normally
rabbits are the most, and mice the least, susceptible [78], and
experimental conditions that produce ectopic bone do not
always coincide with clinical observations in humans.
3.2. Hip Arthroplasty Model. HO is commonly observed
after hip arthroplasty in humans for unknown reasons. To
develop a model relevant to the human condition [44],
Schneider et al. subjected rabbits to surgery analogous to
human hip arthroplasty either with or without muscle and
boneinjuryoneachhip.ThisledtoHO,andtheeﬀectiveness
of postoperative radiation in prophylaxis of HO was then
analyzed using this model. The rationale behind this model
is straightforward, and it can produce HO with certain
reliability; however, despite being a phenocopy of the human
condition, it is not a mechanism-based model. This method
has not been widely adapted by other investigators, probably
due to the relatively complicated surgical procedure.
3.3. The Michelsson Model (Also Called Immobilization
Manipulation Model). Michelsson et al. [45] found that
repeated forced mobilization of an immobilized knee joint
caused HO in the quadriceps muscle in rabbits, and similar
procedures can induce HO around other joints in the
rabbit as well. The precise inductive stimulus has not been
identiﬁed in this model, but an interaction between the
periosteum and the necrotic muscle seems necessary since
the introduction of a plastic membrane between bone and
muscle prevents bone formation [79]. The ﬁrst sign of
osteoblastic activity was seen in the periosteum, and the
new bone was often formed in continuity with the perios-
teum. Interestingly, early changes in prostaglandins preceded
bone formation [80], consistent with the hypothesis that
inﬂammation is the basis of the heterotopic bone formation
in that process. Several authors have used this model to
study the development and prevention of HO in animals
[81–85]. However, since HO in this model is not aﬀected
by denervation, in contradistinction to clinical ﬁndings in
patients with neurologic injuries, the relevance of this model
to human HO is unclear.
3.4. Achilles Tenotomy Model. T h eA c h i l l e st e n o t o m ym o d e l
was ﬁrst described in rats by Buck in 1953 [46], and in
1983, McClure applied the model to mice and found that
ectopic bone developed in 60% of animals by 5 weeks
and in 100% by 10 weeks after Achilles tenotomy [86].
The advantages of this model are its relative simplicity and
excellent predictability. However, the molecular mechanisms
of HO induced by Achilles tenotomy are poorly understood,
and the relevance of this model to clinical conditions is also
unclear since ectopic bone formation in Achilles tendon is a
rareconditioninhumans.Further,inhumansHOisnotonly
associated with prior surgery or trauma to the tendon but is
also an important manifestation of rheumatoid arthritis and
ankylosing spondylitis [86].
3.5. Trauma-Induced Models. Traumatic muscle or CNS
injury often leads to HO in humans, but the underlying
causative factor(s) remains unknown. Eﬀorts to establish
trauma induced models have had only limited success.
Zaccalini and Urist failed to induce HO in rabbit thigh
by blunt force [47]. Walton et al. reported limited success
in inducing HO in sheep thigh by repeated blunt force (7
o u to f4 2s h e e p )[ 48]. Further, intramembranous and not
endochondral ossiﬁcation was the histological feature within
scar tissue. Based on these reports, these models do not
seem to be suﬃciently reliable to be used routinely. Further,
the failure of this strategy has forced us to rethink why
trauma, which clearly plays a role in human HO, does not
routinelyinduceitinsuchmodels.Fortunatelyrecentstudies
using Nse-BMP4 mice have demonstrated that mild trauma
leads to HO with high frequency irrespective of which limb
is injured. In turn this suggests that trauma-induced HO
depends upon susceptibility determined by other factors—
i nt h i sc a s ee l e v a t e dl e v e l so fB M P 4 .T h eh i g hf r e q u e n c ya n d
reproducibility of trauma-induced HO in this model may
provide a means of exploring the underlying mechanisms.
3.6. Irritant and Other Miscellaneous Material-Induced Mod-
els. Injection of various irritant materials into muscle some-
times leads to HO. For example, Heinen et al. reported the
induction of HO in rabbit by injection of 40% ethanol [49].
Selle and Urist also reported that acid-alcohol could induce
HO in a small percent of animals, while injections of calcium
chloride produced only amorphous calciﬁed plaques, not
new bone or cartilage [50]. In addition, Arai et al. [87]
and Caselli et al. [88] reported a controversial ﬁnding that
colchicine induced intramedullary bone formation. This
ﬁnding could not be repeated by K. H. Wlodarski and
P. Wlodarski [89], and later Dudkiewicz et al. found that
colchicine actually inhibits HO in a rabbit model [90]. The
issues of repeatability and relevance of these models to
human HO limits their potential utility.
Overall, due to limited understanding of molecular
mechanisms, most animal models for acquired HO can only
mimic some aspects of the human conditions. Further, the
reliability and questionable clinical relevance hinder their
use as drug test platforms. Thus caution must be taken
in choosing one of these models to be appropriate for the
speciﬁc question being asked.
4. SummaryandFutureDirections
Multiple animal models have been generated for studies of
HO (see Table 1). For the simplicity of description in this
review, we divided these models into two major groups,
acquiredorhereditary.However,tosomeextent,thisdivision
is arbitrary since injury and inﬂammation facilitates and
triggers HO in FOP as well as in animal models of hereditary
HO, and the high variability in susceptibility of diﬀerent
individuals to acquired HO suggests a genetic basis for
individual predisposition. In fact, accumulating clinical and
experimental evidence suggests that similar cellular and
molecular mechanisms underlie the pathophysiology of allJournal of Biomedicine and Biotechnology 5
Table 1: Summary of commonly used animal models.
General strategy examples HO related phenotypes? references
Animal models of
hereditary HO
Hyperactive BMP receptor
ACVR1(R206H) mutation
into zebraﬁsh No HO [20]
Conditionally expresses
caALK2 in mice Embryonic lethal, no HO [29]
Knocking out BMP
inhibitors
Noggin-/- mice Postnatal lethal, skeletal
defects, HO? [30]
Chordin-/- mice Postnatal lethal, skeletal
defects [31]
Overexpressing BMPs
K14-BMP4 No HO [32]
Msx1-BMP4 No observable defects [33]
Nse-BMP4 ProgressiveHO, FOP-like [34]
Overexpressing BMP target
genes
CMV-MSX2, TIMPl-MSX2
or MSX2-MSX2 HO-like [35]
col2-Runx2 HO-like [36]
Modifying BMP signaling
indirectly
H2FosLTR-Fos Calciﬁed tumors similar to
HO [37]
Fos-ES cell chimeras Chondrosarcomas, similar
to HO [38]
Animal models of acquired
HO
Heterotopic implantation
BMP matrigel implantation HO [39]
DNA construct that
produces BMPs HO [40]
Nanogel-cross-linking
hydrogel as a scaﬀold HO [41]
Bone marrow cells HO [42]
Microporous calcium
phosphate ceramic HO [43]
Hip arthroplasty model Hip arthroplasty in rabbits HO [44]
Michelsson model Immobilization
manipulation in rabbits HO [45]
Achilles tenotomy model Achilles tenotomy in rats HO [46]
Trauma-induced model Blunt force in rabbit thigh No HO [47]
Repeated blunt force in
sheep thigh
HO in small % of treated
animals [48]
Inject irritants and other
materials
Injection of 40% ethanol HO [49]
Injection of acid-alcohol HO in small % of treated
animals [50]
typical HO which involves formation of ﬁbroproliferative
lesions containing cells that follow the classic endochondral
ossiﬁcation pathway. Thus, in hereditary HO, a speciﬁc
genetic mutation plays the central role, while in acquired HO
theenvironmentalfactorsplaymoreimportantroles.Forthis
reason, some animal models such as Nse-BMP4 mice can be
used to study both hereditary and acquired HO.
Understanding the fundamental pathophysiology under-
lying HO is the key to development of mechanism-based
animal models. Just as determination of the genetic basis of
FOP opened up a whole new avenue for generating models
for hereditary HO, deeper understanding of the molecular
mechanisms underlying acquired HO will lead to more
fruitful approaches in generating new animal models for
the disorder. Multiple contributing factors are necessary for
acquired HO including a trigger (trauma, injury), osteogenic
progenitor cells, and a permissive microenvironment. How-
ever, thus far there is no single hypothesis that integrates
most clinical and experimental ﬁndings, and current data
strongly suggests the involvement of multiple organ systems
in this disorder. For this reason, future multidisciplinary
studies of neuroimmunological interactions and osteoneu-
roimmunology using currently available animal models,
such as Nse-BMP4 mice, will be necessary to provide the6 Journal of Biomedicine and Biotechnology
new insights which in turn could lay the foundation for new
mechanism-based animal models.
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